LEVICEPT LTD founder and CSO Simon Westbrook explained that LEVI-04's ability to target symptoms and potentially modify the disease could unlock a mega-blockbuster for osteoarthritis in an interview with Kevin Grogan of Citeline's EULAR
Public source
Publisher name
Public post
ARTICLE - In an interview with Kevin Grogan of Citeline's #Scrip during the recent EULAR - European Alliance of Associations for Rheumatology , our founder and CSO Simon…
Company
LEVICEPT LTD
- Industry
- Biotechnology Research
- Company size
- 11–50 employees
About LEVICEPT LTD
Levicept Ltd is a UK-based biotechnology company developing a novel, safe and efficacious biological therapy (LEVI-04 [p75NTR-Fc]) for the treatment of chronic pain. LEVI-04 is currently in a phase II study in patients with osteoarthritis of the knee.
See moreLatest activity
Latest activity from LEVICEPT LTD
3 signals
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Cytonics Corporation
Cytonics Corporation published a new systematic review of 179 randomised knee OA trials showing a pooled placebo effect on pain of 0.63 and 0.71 for intra-articular injection.
Research & Knowledge
Gnosis by Lesaffre
Gnosis by Lesaffre published two separate clinical trials on 600mg chondroitin per day for twelve weeks in the first trial and eight weeks in the second trial, showing a 19 percent drop in WOMAC pain and function scores and a 14 percent improvement in knee function scores.
Research & Knowledge
PERSICA PHARMACEUTICALS LIMITED
PERSICA PHARMACEUTICALS LIMITED published a Phase 1b trial showing that PP353 produced statistically significant and durable improvements in pain and disability over 12 months, along with reduced analgesic use, including opioids.
Research & Knowledge
SCARCELL THERAPEUTICS
Scarcell THERAPEUTICS is currently examining a first-in-human clinical study for aGF Therapy in companion animals with severe osteoarthritis.
Research & Knowledge
GRI Bio, Inc.